Bimekizumab (Bimzelx) is a newer biologic that has shown promising results in phase 3 clinical trials for treating hidradenitis suppurativa (HS). It was approved for psoriasis in 2023 and is currently seeking FDA approval for HS. While some doctors may prescribe it off-label, more research is needed to fully understand its Show Full Answer

Bimekizumab (Bimzelx) is a newer biologic that has shown promising results in phase 3 clinical trials for treating hidradenitis suppurativa (HS). It was approved for psoriasis in 2023 and is currently seeking FDA approval for HS. While some doctors may prescribe it off-label, more research is needed to fully understand its effectiveness and safety for HS. If you have concerns or questions about switching treatments, it's best to discuss them with your healthcare provider.

 This AI-generated response comes from myHSteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Biologics for HS Flares: How I Calm My Treatment Fears | myHSteam

Humira (Adalimumab) for Hidradenitis suppurativa | myHSteam